Neonc Technologies (NASDAQ:NTHI) CEO Thomas Chen Acquires 5,242 Shares of Stock

September 16, 2026 by InsiderTrades.com

Key Points

CEO Amir Heshmatpour bought 15,000 shares at an average price of $3.96, investing $59,400 and increasing his holdings to 3.148 million shares. Other executives also made purchases, signaling management confidence in the stock.
Neonc Technologies reported a quarterly loss of $0.58 per share, missing the $0.12 consensus estimate, while the stock opened at $3.31 and remains well below its 52-week high of $12.99.
The company is advancing its lead therapy NEO100 through Phase 2a development for glioblastoma, but analyst views remain mixed; despite several Buy ratings and high price targets, the overall consensus rating is Hold.

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) CEO Thomas Chen acquired 5,242 shares of the company's stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average cost of $3.81 per share, with a total value of $19,972.02. Following the completion of the purchase, the chief executive officer directly owned 24,503 shares in the company, valued at $93,356.43. This represents a 27.22% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Neonc Technologies Stock Down 12.4%

Shares of NTHI stock opened at $3.31 on Wednesday. The stock has a fifty day moving average price of $4.04 and a 200 day moving average price of $5.27. Neonc Technologies Holdings, Inc. has a 1 year low of $3.01 and a 1 year high of $12.99.

Neonc Technologies (NASDAQ:NTHI - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Neonc Technologies News Roundup

Here are the key news stories impacting Neonc Technologies this week:

Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Analysts Set New Price Targets

A number of brokerages have issued reports on NTHI. Weiss Ratings upgraded shares of Neonc Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, August 31st. BTIG Research reissued a "buy" rating and set a $15.00 price objective on shares of Neonc Technologies in a research note on Tuesday, September 8th. Alliance Global Partners started coverage on Neonc Technologies in a research report on Tuesday, May 19th. They set a "buy" rating and a $13.00 price objective for the company. Finally, Wall Street Zen lowered Neonc Technologies from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $16.00.

Get Our Latest Stock Report on Neonc Technologies

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NTHI. Global Retirement Partners LLC purchased a new position in Neonc Technologies in the 2nd quarter valued at about $126,000. BlackRock Inc. purchased a new stake in shares of Neonc Technologies during the second quarter worth about $815,000. Westmount Partners LLC grew its holdings in shares of Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company's stock worth $893,000 after buying an additional 153,858 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in shares of Neonc Technologies in the second quarter valued at approximately $1,017,000.

Neonc Technologies Company Profile

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.